Dear Editor, In their study, "Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients", the authors report that theirs is the first study "to look at the impact of a VUS result on genetics testing-specific distress following panel gene testing for hereditary breast and ovarian cancer" (Lumish et al. 2017, page 16) .
As a medical oncologist, my experience is typically with the patients similar to those in the large study group (45%), who had a history of breast or ovarian cancer and a negative (normal) genetics test result. The National Comprehensive Cancer Network (NCCN) suggests that for patients with breast or ovarian cancer and a significant family history, but negative BRCA germline testing, recommendations regarding screening and even prophylactic treatment be based on personal and family history (Day et al. 2017) . For patients in this study group, did Lumish et al. determine whether there was a different level of anxiety among patients with a significant family history (FH) compared to patients without a strong FH? In other words, were patients with negative germline testing and a significant family history reassured or was their level of anxiety actually heightened because no explanation for their personal and family history was identified and because the NCCN guideline is consistent with the supposition that their risk should nonetheless be estimated based on personal and FH?
Also, the authors suggest that "while highly penetrant genes such as BRCA1 and BRCA2 have well defined risk profiles and guidelines for clinical management of mutation carriers, mutations in other genes are not yet as well understood and risk profiles are not yet as well understood and the risk profiles are not yet defined to guide clinical management " (Lumish et al. 2017 , page 2). This difference is certainly a reason that one would expect anxiety where guidelines are less well defined. However, I believe it is important to remember that BRCA1 and BRCA2 germline mutations were found to be highly penetrant primarily based on studies involving patients with a higher pre-test probability than the pre-test probability of many patients who are now tested. It is understandable that a patient might be less anxious (due to less uncertainty) by hearing very specific risks and recommendations related to BRCA1 or BRCA2 germline mutations, but is it proven that these risks apply to a patient who tests positive but has no significant family history?
For patients with breast cancer and a strong FH who have negative germline testing, I believe future studies should explore their reactions to negative test results, in the setting of the current (almost paradoxical) recommendation regarding screening and prophylactic measures to consider in the face of a negative germline BRCA testing result. Also, until the significance of testing positive for a germline BRCA mutation with a truly low pre-test probability (eg minimal possibility of a de novo mutation or erroneous FH) is determined, one must consider the anxiety generated by a positive BRCA1 or BRCA2 result despite the generally accepted high penetrance for patients harboring a BRCA mutation.
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